A detailed history of Tocqueville Asset Management L.P. transactions in Abb Vie Inc. stock. As of the latest transaction made, Tocqueville Asset Management L.P. holds 310,430 shares of ABBV stock, worth $55.9 Million. This represents 0.98% of its overall portfolio holdings.

Number of Shares
310,430
Previous 316,033 1.77%
Holding current value
$55.9 Million
Previous $54.2 Million 13.09%
% of portfolio
0.98%
Previous 0.9%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$163.84 - $199.33 $917,995 - $1.12 Million
-5,603 Reduced 1.77%
310,430 $61.3 Million
Q2 2024

Aug 12, 2024

BUY
$154.79 - $180.76 $7.61 Million - $8.89 Million
49,186 Added 18.43%
316,033 $54.2 Million
Q1 2024

May 09, 2024

SELL
$159.82 - $182.1 $394,435 - $449,422
-2,468 Reduced 0.92%
266,847 $48.6 Million
Q4 2023

Feb 12, 2024

SELL
$137.6 - $154.97 $794,640 - $894,951
-5,775 Reduced 2.1%
269,315 $41.7 Million
Q3 2023

Nov 09, 2023

SELL
$133.59 - $154.65 $726,195 - $840,677
-5,436 Reduced 1.94%
275,090 $41 Million
Q2 2023

Aug 11, 2023

SELL
$132.51 - $164.9 $335,382 - $417,361
-2,531 Reduced 0.89%
280,526 $37.8 Million
Q1 2023

May 10, 2023

SELL
$144.61 - $166.54 $256,538 - $295,441
-1,774 Reduced 0.62%
283,057 $45.1 Million
Q4 2022

Feb 09, 2023

BUY
$138.31 - $165.87 $810,358 - $971,832
5,859 Added 2.1%
284,831 $46.1 Million
Q3 2022

Nov 10, 2022

SELL
$134.21 - $153.93 $269,359 - $308,937
-2,007 Reduced 0.71%
278,972 $37.4 Million
Q2 2022

Aug 12, 2022

BUY
$137.62 - $174.96 $807,003 - $1.03 Million
5,864 Added 2.13%
280,979 $43 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $1.06 Million - $1.32 Million
-8,053 Reduced 2.84%
275,115 $44.6 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $223,454 - $282,734
2,080 Added 0.74%
283,168 $38.3 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $100,016 - $113,533
940 Added 0.34%
281,088 $30.3 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $83,641 - $93,181
795 Added 0.28%
280,148 $31.6 Million
Q1 2021

May 17, 2021

SELL
$102.3 - $112.62 $106,392 - $117,124
-1,040 Reduced 0.37%
279,353 $30.2 Million
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $50,145 - $67,701
623 Added 0.22%
280,393 $30 Million
Q3 2020

Nov 16, 2020

BUY
$85.91 - $100.83 $20,360 - $23,896
237 Added 0.08%
279,770 $24.5 Million
Q2 2020

Aug 12, 2020

BUY
$73.37 - $98.18 $881,320 - $1.18 Million
12,012 Added 4.49%
279,533 $27.4 Million
Q1 2020

May 15, 2020

SELL
$64.5 - $97.79 $1.27 Million - $1.92 Million
-19,684 Reduced 6.85%
267,521 $20.4 Million
Q4 2019

Jan 14, 2020

SELL
$72.13 - $90.25 $737,529 - $922,806
-10,225 Reduced 3.44%
287,205 $25.4 Million
Q3 2019

Oct 31, 2019

BUY
$62.98 - $75.72 $409,684 - $492,558
6,505 Added 2.24%
297,430 $22.5 Million
Q2 2019

Jul 31, 2019

BUY
$65.7 - $83.98 $2.53 Million - $3.24 Million
38,561 Added 15.28%
290,925 $21.2 Million
Q1 2019

Apr 30, 2019

SELL
$77.14 - $90.79 $903,772 - $1.06 Million
-11,716 Reduced 4.44%
252,364 $20.3 Million
Q4 2018

Feb 08, 2019

SELL
$77.85 - $96.01 $11.5 Million - $14.2 Million
-148,157 Reduced 35.94%
264,080 $24.3 Million
Q3 2018

Nov 13, 2018

SELL
$88.91 - $98.84 $123,140 - $136,893
-1,385 Reduced 0.33%
412,237 $39 Million
Q2 2018

Aug 13, 2018

SELL
$89.78 - $106.23 $6.65 Million - $7.87 Million
-74,054 Reduced 15.19%
413,622 $38.3 Million
Q1 2018

May 14, 2018

SELL
$92.01 - $123.21 $4.05 Million - $5.42 Million
-44,002 Reduced 8.28%
487,676 $46.2 Million
Q4 2017

Feb 13, 2018

SELL
$89.56 - $98.21 $1.03 Million - $1.13 Million
-11,467 Reduced 2.11%
531,678 $51.4 Million
Q3 2017

Oct 30, 2017

BUY
$69.85 - $89.22 $37.9 Million - $48.5 Million
543,145
543,145 $48.3 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Tocqueville Asset Management L.P. Portfolio

Follow Tocqueville Asset Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Tocqueville Asset Management L.P. with notifications on news.